10-Q: Ginkgo Bioworks Reports Q3 2024 Results, Revenue Growth Driven by Cell Engineering

Ginkgo Bioworks saw a significant increase in Cell Engineering revenue in Q3 2024, while also reporting a net loss and restructuring charges.

Summary

• Ginkgo Bioworks reported a net loss of $56.4 million for the third quarter of 2024, compared to a net loss of $302.9 million in the same period of 2023.
• Cell Engineering revenue increased to $75.1 million in Q3 2024, up from $37.2 million in Q3 2023, driven by progress in active programs and the recognition of $45.4 million in non-cash revenue from the termination of a contract with Motif FoodWorks.
• Biosecurity revenue decreased to $20.5 million in Q3 2024, down from $40.7 million in Q3 2023, due to the end of COVID-19 testing programs, partially offset by growth in biomonitoring and bioinformatic support services.
• The company incurred restructuring charges of $2.9 million in Q3 2024, related to workforce reductions and facility consolidation.
• Ginkgo recorded a goodwill impairment charge of $47.9 million in the nine months ended September 30, 2024.
• The company's cash and cash equivalents totaled $616.2 million as of September 30, 2024.
• The company's total revenue for the nine months ended September 30, 2024 was $183.2 million, compared to $216.7 million for the same period in 2023.
• The net loss for the nine months ended September 30, 2024 was $439.5 million, compared to a net loss of $681.2 million for the same period in 2023.

Sentiment

Score: 4

Explanation: The document presents mixed results. While Cell Engineering revenue is growing, the company is still operating at a loss, has incurred significant impairment charges, and is undergoing restructuring. The sentiment is therefore cautiously negative.

Positives

• Cell Engineering revenue showed strong growth, indicating increased demand for Ginkgo's cell programming services.
• The company's restructuring plan is expected to reduce operational expenditures.
• Ginkgo launched new customer offerings, expanding its product portfolio.
• The company has a substantial cash balance of $616.2 million.

Negatives

• The company reported a net loss of $56.4 million for Q3 2024.
• Biosecurity revenue decreased due to the end of COVID-19 testing programs.
• Ginkgo incurred a significant goodwill impairment charge of $47.9 million.
• The company incurred restructuring charges of $2.9 million in Q3 2024.

Risks

• The company's restructuring plan may not result in anticipated savings and could disrupt the business.
• Ginkgo is exposed to risks related to holding equity interests in certain customers.
• The company faces intense competition in the synthetic biology industry.
• Ginkgo's ability to raise financing in the future is uncertain.
• The company is still working to remediate a material weakness in internal control over financial reporting.

Future Outlook

The company expects to continue its restructuring efforts, including workforce reductions and facility consolidation, through 2025. Ginkgo also anticipates continued growth in its Cell Engineering business and expansion of its Biosecurity offerings.

Management Comments

• Management believes that the company's cash and cash equivalents will be sufficient to fund operations for at least the next 12 months.
• Management is committed to the remediation of the material weakness in internal control over financial reporting.

Industry Context

Ginkgo's results reflect the ongoing growth and challenges in the synthetic biology industry. The company's focus on cell programming and biosecurity aligns with broader trends in biotechnology and public health. The company's restructuring efforts are indicative of the need for cost management in a competitive market.

Comparison to Industry Standards

• Ginkgo's Cell Engineering revenue growth is notable compared to some other synthetic biology companies, but the company's overall profitability remains a challenge.
• The company's Biosecurity revenue decline reflects the broader shift away from COVID-19 testing, which has impacted many companies in the diagnostics space.
• The goodwill impairment charge is a significant event, indicating a potential overvaluation of assets and a need for more conservative accounting practices.
• The company's restructuring plan is similar to actions taken by other companies in the tech and biotech sectors facing economic headwinds.

Related Party Transactions

• The company had significant related party transactions with Motif FoodWorks, Allonnia, Genomatica, BiomEdit, Ayana Bio, and Arcaea.
• The company recognized $45.4 million in non-cash revenue from the termination of a contract with Motif FoodWorks.

Stakeholder Impact

• Shareholders are impacted by the net loss and goodwill impairment.
• Employees are affected by the workforce reductions as part of the restructuring plan.
• Customers may experience changes in service offerings and pricing due to the restructuring.
• Suppliers may be impacted by changes in the company's operations and spending.

Next Steps

• The company will continue to implement its restructuring plan.
• Ginkgo will focus on growing its Cell Engineering business and expanding its Biosecurity offerings.
• The company will continue to remediate the material weakness in internal control over financial reporting.

Key Dates

Keywords

Cell Engineering, Biosecurity, Synthetic Biology, Restructuring, Goodwill Impairment, Revenue, Net Loss, Financial Results, Ginkgo Bioworks, Biomonitoring